Henry G. Kaplan

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With <i>BRAF</i> Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study

MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2–Positive and/or Hormone Receptor–Negative Breast Cancers in the I-SPY 2 Trial

Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders

Metastatic breast cancer survival improvement restricted by regional disparity: Surveillance, Epidemiology, and End Results and institutional analysis: 1990 to 2011

Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint

Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer

Adaptive Randomization of Neratinib in Early Breast Cancer

Abstract CT042: Efficacy of T-DM1+pertuzumab over standard therapy for HER2+ breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer

Effect of treatment and mammography detection on breast cancer survival over time: 1990‐2007

Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer

Adaptively randomized trial of neoadjuvant chemotherapy with or without the Akt inhibitor MK-2206: Graduation results from the I-SPY 2 Trial.

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Pharmacokinetics of doxorubicin in pregnant women